StockData

Coherus Oncology vs Fennec Pharmaceuticals

CHRS and FENC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CHRS and FENC compare

Fennec Pharmaceuticals is the larger company, worth 6.4 times as much as Coherus Oncology ($476M against $73.9M).

Fennec Pharmaceuticals grew revenue faster over the last twelve months (77.8% versus 61.0% for Coherus Oncology).

Fennec Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −5.5% compared with −259% at Coherus Oncology.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCHRSFENC
Size and price
Market cap$73.9M$476M
Share price$0.478$13.58
Change, 1 year−59.8%72.8%
Change, 5 years−97.4%40.9%
Beta (5Y)0.881.89
Employees14735
StockData Score
Total score77
Valuation score3 (better)0
Growth score22
Performance score13 (better)
Health score12 (better)
Dividend score00
Valuation
P/S1.5× (better)8.0×
P/B1.2× (better)11.2×
Fair value$1.16$7.22
Margin of safety58.8% (better)−88.0%
Growth
Revenue growth (TTM)61.0%77.8% (better)
Revenue growth, 5Y average−38.4%195% (better)
Net income growth (TTM)−174%–
EPS growth, 5Y average−2.5%–
Profitability
Gross margin68.9%–
Operating margin−312%−1.9% (better)
Net margin−259%−5.5% (better)
Return on equity−146%−18.6% (better)
Financial health
Interest coverage−17.5×−1.2× (better)
Current ratio1.775.85 (better)
Altman Z-score−12.336.06 (better)
Piotroski F-score6 (better)1
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions45.5%46.5%
Held by insiders1.3%–
Insider net buying, 12 months–−$9.9M
Short interest, % of float8.3%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.